| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 63539-0252-02 | 63539-0252 | Elranatamab-bcmm | Elrexfio | 44.0 mg/1.1mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug 15, 2023 | In Use | |
| 55513-0710-01 | 55513-0710 | Denosumab | Prolia | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 5, 2010 | In Use | |
| 78206-0147-01 | 78206-0147 | trastuzumab | Ontruzant | 150.0 mg/1 | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jun 1, 2021 | In Use | |
| 61314-0228-94 | 61314-0228 | Denosumab | WYOST | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 2, 2025 | In Use | |
| 57894-0449-01 | 57894-0449 | Teclistamab | TECVAYLI | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Oct 25, 2022 | In Use | |
| 00173-0821-33 | 00173-0821 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jul 22, 2011 | Aug 31, 2017 | No Longer Used |
| 00024-0654-01 | 00024-0654 | Isatuximab | Sarclisa | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Mar 2, 2020 | In Use | |
| 50242-0108-86 | 50242-0108 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | Jun 23, 2017 | In Use | |
| 55513-0160-01 | 55513-0160 | Blinatumomab | Blincyto | Immunotherapy | Monoclonal Antibody | CD3 (T cells) and CD19 (B cells) | Intravenous | Dec 18, 2014 | In Use | ||
| 82705-0002-01 | 82705-0002 | Epcoritamab-bysp | EPKINLY | 4.0 mg/.8mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Subcutaneous | May 19, 2023 | In Use | |
| 00069-0308-01 | 00069-0308 | trastuzumab-qyyp | Trazimera | 150.0 mg/7.15mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Mar 10, 2021 | In Use | |
| 50242-0060-01 | 50242-0060 | Bevacizumab | Avastin | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Feb 26, 2004 | In Use | |
| 50242-0132-10 | 50242-0132 | Trastuzumab | Herceptin | 150.0 mg/7.4mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jun 3, 2019 | In Use | |
| 50242-0159-01 | 50242-0159 | Mosunetuzumab | Lunsumio | 1.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Intravenous | Dec 22, 2022 | In Use | |
| 55513-0956-01 | 55513-0956 | Panitumumab | Vectibix | 400.0 mg/20mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct 10, 2006 | In Use | |
| 55513-0141-21 | 55513-0141 | trastuzumab-anns | Kanjinti | 150.0 mg/7.15mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jul 1, 2025 | In Use | |
| 55513-0206-21 | 55513-0206 | Bevacizumab-awwb | MVASI | 100.0 mg/4mL, 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jun 27, 2025 | In Use | |
| 00078-0669-61 | 00078-0669 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Feb 1, 2016 | In Use | |
| 50242-0245-86 | 50242-0245 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | May 3, 2021 | In Use | |
| 74527-0022-03 | 74527-0022 | margetuximab-cmkb | MARGENZA | 25.0 mg/mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jan 15, 2021 | In Use | |
| 00069-0342-01 | 00069-0342 | Bevacizumab-bvzr | Zirabev | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jan 13, 2020 | In Use | |
| 00078-0669-13 | 00078-0669 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Feb 1, 2016 | In Use | |
| 66733-0958-23 | 66733-0958 | Cetuximab | Erbitux | 2.0 mg/mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct 2, 2007 | In Use | |
| 50242-0142-01 | 50242-0142 | Mosunetuzumab | Lunsumio | 30.0 mg/30mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Intravenous | Dec 22, 2022 | In Use | |
| 70121-1754-01 | 70121-1754 | Bevacizumab-maly | ALYMSYS | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGF | Intravenous | Apr 15, 2022 | In Use |
Found 11888 results — Export these results
Home